Blueprint Medicines Q1 2022 Earnings Report
Key Takeaways
Blueprint Medicines achieved $23.8 million in AYVAKIT® net product revenues and $62.7 million in total revenues. They are on track to report topline data for the registration-enabling PIONEER trial of AYVAKIT in non-advanced SM in late summer 2022.
Achieved $23.8 million in AYVAKIT® (avapritinib) net product revenues, and $62.7 million in total revenues
AYVAKYT® (avapritinib) launch in Germany underway following European Commission approval for advanced SM on March 25
First patients dosed in BLU-701, BLU-451, and BLU-222 clinical trials; trial cohort initiated for BLU-945 in combination with osimertinib
On track to report topline data for registration-enabling PIONEER trial of AYVAKIT in non-advanced SM in late summer 2022
Blueprint Medicines
Blueprint Medicines
Forward Guidance
Blueprint Medicines continues to anticipate approximately $180 to $200 million in total net revenues in 2022, including approximately $115 to $130 million in AYVAKIT net product revenues. The company continues to expect that its existing cash, cash equivalents and investments, together with anticipated future product revenues, will provide sufficient capital to enable the company to achieve a self-sustainable financial profile.